The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Drugging the Cancer Chaperone HSP90: Combinatorial Therapeutic Exploitation of Oncogene Addiction and Tumor Stress
Abstract
The molecular chaperone HSP90 has emerged as an exciting target for cancer treatment. We review the potential advantages of HSP90 inhibitors, particularly the simultaneous combinatorial depletion of multiple oncogenic “client” proteins, leading to blockade of many cancer‐causing pathways and the antagonism of all of the hallmark pathological traits of malignancy. Cancer selectivity is achieved by exploiting cancer “dependencies,” including oncogene addiction and the stressed state of malignant cells. The multiple downstream effects of HSP90 inhibitors should make the development of resistance more difficult than with agents having more restricted effects. We review the various classes of HSP90 inhibitor that have been developed, including the natural products geldanamycin and radicicol and also the purine scaffold and pyrazole/isoxazole class of synthetic small molecule inhibitors. A first‐in‐class HSP90 drug, the geldanamycin analog 17‐AAG, has provided proof of concept for HSP90 inhibition in patients at well tolerated doses and therapeutic activity has been seen. Other inhibitors show promise in preclinical and clinical development. Opportunities and challenges for HSP90 inhibitors are discussed, including use in combination with other agents. Most of the current HSP90 inhibitors act by blocking the essential nucleotide binding and ATPase activity required for chaperone function. Potential new approaches are discussed, for example, interference with cochaperone binding and function in the superchaperone complex. Biomarkers for use with HSP90 inhibitors are described. We stress how basic and translational research has been mutually beneficial and indicate future directions to enhance our understanding of molecular chaperones and their exploitation in cancer and other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sain, N., Krishnan, B., Ormerod, M. G., Rienzo, A. D., Liu, W. M., Kaye, S. B., Workman, P., & Jackman, A. L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0445 · Cited by 92
Self-citationRetractedThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Self-citationHSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270
A new puffing pattern induced by temperature shock and DNP in drosophila
Ritossa, F. (1962) · Experientia · doi:10.1007/bf02172188 · Cited by 2,068
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
Self-citation
Cited by
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Targeting the dynamic HSP90 complex in cancer
Trepel, J., Mollapour, M., Giaccone, G., & Neckers, L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2887 · Cited by 1,514
Self-citationHsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Neckers, L., & Workman, P. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1000 · Cited by 891
Self-citationLenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508
Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach
Chatterjee, S., & Burns, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091978 · Cited by 501
Staudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Eccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5256 · Cited by 479
Self-citationAdvances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
Jhaveri, K., Taldone, T., Modi, S., & Chiosis, G. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.10.008 · Cited by 456
The Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Self-citationBrough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K.-M. J., Collins, I., Davies, N. G. M., Drysdale, M. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701018h · Cited by 444
Self-citationModi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M. E., Sugarman, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0072 · Cited by 424
Self-citationCowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413
Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic
Talele, T., Khedkar, S., & Rigby, A. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790232251 · Cited by 407
The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases
Lackie, R. E., Maciejewski, A., Ostapchenko, V. G., Marques-Lopes, J., Choy, W.-Y., Duennwald, M. L., Prado, V. F., & Prado, M. A. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00254 · Cited by 374
Regulation and function of the human HSP90AA1 gene
Zuehlke, A. D., Beebe, K., Neckers, L., & Prince, T. (2015) · Gene · doi:10.1016/j.gene.2015.06.018 · Cited by 347
Self-citationSequist, L. V., Gettinger, S., Senzer, N. N., Martins, R. G., Jänne, P. A., Lilenbaum, R., Gray, J. E., Iafrate, A. J., Katayama, R., Hafeez, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8338 · Cited by 330
Chou, T.-F., Brown, S. J., Minond, D., Nordin, B. E., Li, K., Jones, A. C., Chase, P., Porubsky, P. R., Stoltz, B. M., Schoenen, F. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015312108 · Cited by 324
Caldas-Lopes, E., Cerchietti, L., Ahn, J. H., Clement, C. C., Robles, A. I., Rodina, A., Moulick, K., Taldone, T., Gozman, A., Guo, Y., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903392106 · Cited by 315
Aneuploidy causes proteotoxic stress in yeast
Oromendia, A. B., Dodgson, S. E., & Amon, A. (2012) · Genes & Development · doi:10.1101/gad.207407.112 · Cited by 313
Mechanisms of proteasome inhibitor action and resistance in cancer
McConkey, D. J., & Zhu, K. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.08.002 · Cited by 309
Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis
Powers, M. V., Clarke, P. A., & Workman, P. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.002 · Cited by 307
Self-citationDiscovering Anti-Cancer Drugs via Computational Methods
Cui, W., Aouidate, A., Wang, S., Yu, Q., Li, Y., & Yuan, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00733 · Cited by 307
Probing the Probes: Fitness Factors For Small Molecule Tools
Workman, P., & Collins, I. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.013 · Cited by 299
Self-citationPost-translational modifications of Hsp90 and their contributions to chaperone regulation
Mollapour, M., & Neckers, L. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.07.018 · Cited by 288
Self-citationTargeting Hsp90: small-molecule inhibitors and their clinical development
Taldone, T., Gozman, A., Maharaj, R., & Chiosis, G. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.015 · Cited by 284
Hsp60 expression, new locations, functions, and perspectives for cancer diagnosis and therapy
Cappello, F., Conway de Macario, E., Marasà, L., Zummo, G., & Macario, A. J. L. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.6.6281 · Cited by 280
O’Brien, K., Lowry, M. C., Corcoran, C., Martinez, V. G., Daly, M., Rani, S., Gallagher, W. M., Radomski, M. W., MacLeod, R. A. F., & O’Driscoll, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5192 · Cited by 273
Secondary metabolites from entomopathogenic Hypocrealean fungi
Molnár, I., Gibson, D. M., & Krasnoff, S. B. (2010) · Natural Product Reports · doi:10.1039/c001459c · Cited by 271
HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy
WANG, X., CHEN, M., ZHOU, J., & ZHANG, X. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2399 · Cited by 269
Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update
Ciocca, D. R., Arrigo, A. P., & Calderwood, S. K. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0918-z · Cited by 265
Woodhead, A. J., Angove, H., Carr, M. G., Chessari, G., Congreve, M., Coyle, J. E., Cosme, J., Graham, B., Day, P. J., Downham, R., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100060b · Cited by 264
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90
Moulick, K., Ahn, J. H., Zong, H., Rodina, A., Cerchietti, L., Gomes DaGama, E. M., Caldas-Lopes, E., Beebe, K., Perna, F., Hatzi, K., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.670 · Cited by 261
Self-citationHong, D. S., Banerji, U., Tavana, B., George, G. C., Aaron, J., & Kurzrock, R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.10.001 · Cited by 259
Smith, D. F., & Toft, D. O. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0089 · Cited by 173
Hsp90: A New Player in DNA Repair?
Pennisi, R., Ascenzi, P., & Di Masi, A. (2015) · Biomolecules · doi:10.3390/biom5042589 · Cited by 112
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Jacobson, C., Kopp, N., Layer, J. V., Redd, R. A., Tschuri, S., Haebe, S., van Bodegom, D., Bird, L., Christie, A. L., Christodoulou, A., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711176 · Cited by 45
Metabolic control of antifungal drug resistance
Robbins, N., Collins, C., Morhayim, J., & Cowen, L. E. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.07.004 · Cited by 40
Metadata
- Authors
- WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2007-10
- Volume
- 1113
- Issue
- 1
- Pages
- 202-216
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2042985720
- Cited by
- 521
- References
- 88
- FWCI
- 15.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.